전체기사보기
날짜선택-
-
[단독외신] Smiths Detection enters into agreement to acquire PathSensors to expand its biological-detection capability
- [단독외신] Smiths Detection enters into agreement to acquire PathSensors to expand its biological-detection capability Smiths Detection, a global leader in detection and screening technologies, today announces that it has entered into an agreement to acquire PathSensors, a leading bio-technology solutions and environmental-testing company based in Baltimore, MD. The acquisition expands Smiths Detection’s sensing capabilities across the CBRNE (chemical, biological, radiological, nuclear and explosive) spectrum to respond quickly to emerging threats. PathSensors provides high-speed, highly sensitive pathogen-detection and biothreat solutions and has developed a robust fieldable method of identifying biological threats in minutes. The company shares a similar customer base to that which Smiths Detection serves for chemical-threat detection, while also offering an expanded end-use market into adjacent security markets such as food and agricultural safety. PathSensors offers multiple assays that are already available, at an independently verified speed and sensitivity data, which offer an opportunity to develop their future potential. The transaction will enable Smiths Detection to accelerate its position in biological-detection capabilities which are important both within our current markets and beyond. “The acquisition of PathSensors will allow us to broaden our detection capabilities within the biological spectrum, which is becoming more relevant in the current environment,” said Roland Carter, President of Smiths Detection. “This is consistent with our approach to increase our focus on investing selectively in technology and innovation for the purpose of getting closer to our customers and expanding into new markets.” The contract is subject to customary closing conditions and is expected to conclude within the next four weeks.
-
- Animal Rights
-
[단독외신] Smiths Detection enters into agreement to acquire PathSensors to expand its biological-detection capability
-
-
[단독외신] EUSA Pharma Announces FDA Approval of Phase 3 Clinical Trial for Siltuximab in Hospitalized Patients With COVID-19 Associated Acute Respiratory Distress Syndrome
- EUSA Pharma Announces FDA Approval of Phase 3 Clinical Trial for Siltuximab in Hospitalized Patients With COVID-19 Associated Acute Respiratory Distress Syndrome EUSA Pharma, a global biopharmaceutical company focused on oncology and rare disease, today announced that the U.S. Food & Drug Administration (FDA) has approved a randomized, double-blind, placebo-controlled Phase 3 clinical trial protocol to evaluate the safety and efficacy of intravenous siltuximab plus standard of care in hospitalized patients with COVID-19 associated Acute Respiratory Distress Syndrome (ARDS). Siltuximab is a monoclonal antibody that directly neutralizes interleukin (IL)-6, an inflammatory cytokine detected at elevated levels in multiple inflammatory conditions, including COVID-19. It specifically binds to IL-6, thereby inactivating IL-6 induced signalling. Lee Morley, Chief Executive Officer, EUSA Pharma, said: “Since the start of the pandemic, a growing body of evidence has been published highlighting that COVID-19 associated ARDS may exhibit features of systemic hyperinflammation, resulting from excessive cytokine production - the so-called ‘cytokine storm’ - with IL-6 recognized as a key driver of this severe condition. Treatment approaches neutralizing IL-6 could therefore play a key role in mitigating further detrimental inflammation and progression to respiratory failure, which can be fatal. We thank the FDA for recognizing the importance of this clinical trial and the quick approval we received. Our plan now is to initiate the study as quickly as possible with the hope of seeing improved clinical outcomes in these critically ill patients.” To date, several independent clinical trials have begun globally to explore the safety and efficacy of siltuximab for the treatment of severe COVID-19 patients. Final results from the Papa Giovanni XXIII Hospital sponsored SISCO[1] (Siltuximab In Serious COVID-19) Study, an observational cohort control trial investigating siltuximab plus standard of care in COVID-19 patients with serious respiratory complications, are available via pre-print summary here (https://bit.ly/3ioH9vW).[2] However, the newly approved confirmatory clinical trial is vital because these findings require validation in a well-controlled randomized study and there is limited published data on the safety and efficacy of siltuximab in COVID-19. Siltuximab is also not yet FDA-approved for complications associated with COVID-19.
-
- Animal Rights
-
[단독외신] EUSA Pharma Announces FDA Approval of Phase 3 Clinical Trial for Siltuximab in Hospitalized Patients With COVID-19 Associated Acute Respiratory Distress Syndrome
-
-
아바타메드, 나노포커스레이와 ‘코로나19 진단용 이동형 CT’ 해외판매 협약 체결
- 아바타메드, 나노포커스레이와 ‘코로나19 진단용 이동형 CT’ 해외판매 협약 체결
-
- NEWS & ISSUE
- Social
-
아바타메드, 나노포커스레이와 ‘코로나19 진단용 이동형 CT’ 해외판매 협약 체결
-
-
속보Northern Data: SBI Becomes New Strategic Shareholder
- Northern Data: SBI Becomes New Strategic Shareholder Northern Data AG (XETRA: NB2, ISIN: DE000A0SMU87), one of the world's largest providers of high-performance computing (HPC) solutions, is now welcoming SBI Crypto as a new strategic shareholder. SBI Crypto Co., Ltd., is a wholly-owned subsidiary of SBI Holdings Inc. (Tokyo: 8473) engaging in the areas of cryptocurrency mining. SBI Crypto is one of the first enterprises hosted at Northern Data's new Texas facility and became a strategic partner for projects relating to blockchain technology infrastructure and joint software development and deployment. SBI Crypto was one of the holders of the convertible bond issued in November 2019. Together with other strategic partners, which represent the majority of the convertible bondholders, SBI Crypto converted into stock. The strategic shareholders have agreed to a lock-up of up to 36 months subject to customary exceptions. “There are a lot of synergies available between SBI Group and Northern Data. We look forward to increased cooperation. We have high expectations of them, including software development and producing a positive impact to the energy grid,” explains Carson Smith, CEO of SBI Crypto. Aroosh Thillainathan, CEO of Northern Data AG commented as follows: “The first half of 2020 can be seen as a breakthrough for our company, as we moved from the developing and testing phase of the past years into scaling our business with world-class customers and partners. Turning them into strategic shareholders feels like the best possible confirmation that we are on the right track. I am confident that we have everything in place to write an impressive and sustainable success story from where we stand today. We are grateful for the support of our shareholders and are looking forward to continuing our exciting journey with you.” SBI Crypto is one of Northern Data's first two major clients that are now live at the new Texas facility. These initial revenues will be detailed in the half-year figures to June 30, 2020, which will be released in September. In addition to the all-new facility in Texas, Northern Data is developing additional sites in Canada and Scandinavia in order to meet overwhelming customer demand. The innovative design of these new facilities is currently in its final stage and the company is planning to officially disclose the locations within the upcoming weeks. Construction will commence shortly after this announcement and the go-live date is targeted for Q1 2021.
-
- Animal Rights
-
속보Northern Data: SBI Becomes New Strategic Shareholder